Here's Why Auris (CYTO) Is a Great 'Buy the Bottom' Stock Now
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 15 2024
0mins
Source: NASDAQ.COM
Stock Performance and Technical Analysis: Altamira Therapeutics (CYTO) has seen a 16.6% decline in shares over the past month, but the formation of a hammer chart pattern suggests potential support and a trend reversal, supported by rising optimism from Wall Street analysts regarding future earnings.
Earnings Estimates and Zacks Rank: The consensus EPS estimate for CYTO has increased by 37.8% over the last 30 days, indicating improved earnings expectations, and the stock holds a Zacks Rank #2 (Buy), suggesting strong potential for outperformance in the market.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
